Replies to post #127347 on Biotech Values

[bladerunner1717]

Peter,

Assuming that Ponatinib gets approved for third-line therapy, would reimbursement issues prevent doctors from using Ponatinib in first-line or second-line, if they chose to do so?


Bladerunner

[biomaven0]

63% CCyR response for pona in 3rd-line patients is quite comparable to the 66% figure for Gleevec in 1st-line patients.

Reviewing this more carefully, it looks like I overstated this a bit. The pona number is "best response" while the Gleevec number is 12 month response. They don't give the 12-month CCyR number for pona, but the MCyR best response was 72% and the MCyR 12-month was 69%, so the difference for CCyR is also likely only a couple of percent.

Peter